EX-99.1 2 ex99-1.htm EX-99.1

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1
Name and Address of Company
   
 
Vasogen Inc.
 
2505 Meadowvale Blvd
 
Mississauga, ON
 
L5N 5S2
   
Item 2
Date of Material Change
   
 
June 26, 2006
   
Item 3
News Release
   
 
A press release with respect to the material change described herein was issued on June 26, 2006 via Canada NewsWire and filed on SEDAR.
   
Item 4
Summary of Material Change
   
 
Vasogen Announces Initial Results from Phase III ACCLAIM Trial in Chronic Heart Failure
   
Item 5
Full Description of Material Change
   
 
Vasogen Inc. announced initial results from the 2, 414-patient phase III ACCLAIM trial of its Celacade technology (Celacade) in advanced chronic heart failure (HF). While the ACCLAIM study did not reach the primary endpoint of significantly reducing the risk of death and cardiovascular hospitalization in the total population, this endpoint was met for the subgroup of 692 patients with New York Heart Association (NYHA) Class II chronic HF (39.1% risk reduction, p=0.0003). The Company is continuing data analysis, and complete results for the ACCLAIM study are scheduled to be presented at the World Congress of Cardiology 2006, being held from September 2-6 in Barcelona, Spain.
   
Item 6
Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
   
 
Confidentiality is not requested
   
Item 7
Omitted Information
   
 
Not applicable
 
 
 
 
 
 

   
Item 8
Executive Officer
   
 
For further information contact Glenn Neumann, Investor Relations of Vasogen, Inc. at (905) 569-9065.

The foregoing accurately discloses the material change referred to herein.

DATED at Toronto, Ontario this 26th day of June, 2006.


 
VASOGEN INC.
     
     
     
     
 
   /s/ Jacqueline H.R. Le Saux    
 
By: 
Jacqueline H.R. Le Saux
   
Vice President, Corporate &
 
  
Legal Affairs